Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas

Authors: Elise A. Chong, Elicia Penuel, Ellen B. Napier, Rachel K. Lundberg, Lihua E. Budde, Mazyar Shadman, Matthew J. Matasar, Nancy L. Bartlett, Ian W. Flinn, Francesc Bosch, Keith Fay, Andre Goy, Anita Kumar, Loretta J. Nastoupil, Michael C. Wei, Mei Wu, Shen Yin, Joseph A. Fraietta, Emeline R. Chong, Stephen J. Schuster

Contributors: Institut Català de la Salut, [Chong EA, Napier EB, Lundberg RK] Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA. [Penuel E] Genentech, Inc, South San Francisco, USA. [Budde LE] Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, USA. [Shadman M] Clinical Research Division, Fred Hutchinson Cancer Center and Hematology and Medical Oncology Division, University of Washington, Seattle, USA. [Bosch F] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Blood Adv
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Blood Advances, Vol 9, Iss 4, Pp 696-703 (2025)

Subject Terms: Male, Adult, 0301 basic medicine, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Cèl·lules B - Tumors - Immunoteràpia, Lymphoma, B-Cell, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Clinical Trials and Observations, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B, Specialties of internal medicine, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Antibodies, Monoclonal, Humanized, Immunotherapy, Adoptive, Limfomes - Immunoteràpia, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell, 03 medical and health sciences, Recurrence, Antibodies, Bispecific, Humans, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Aged, 0303 health sciences, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Receptors, Chimeric Antigen, Anticossos monoclonals - Ús terapèutic, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Middle Aged, Treatment Outcome, RC581-951, Female

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39571171
http://hdl.handle.net/11351/12836
https://doaj.org/article/ccaea24960464786b8012cda2e6aebdb

Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example

Authors: Pérez Raya , María, IACOBONI, GLORIA

Contributors: Institut Català de la Salut, [Iacoboni G] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pérez Raya M] Department of Hematology, Regional University Hospital, Málaga, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Oncol Ther
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Oncology and Therapy, Vol 13, Iss 1, Pp 11-16 (2024)

Subject Terms: DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Cèl·lules B - Tumors - Immunoteràpia, Other subheadings::Other subheadings::Other subheadings::/drug therapy, High risk, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, CAR T-cell therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Limfomes - Immunoteràpia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, DLBCL, Avaluació de resultats (Assistència sanitària), Commentary, Real-world outcomes, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, RC254-282

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39680322
http://hdl.handle.net/11351/12819
https://doaj.org/article/71c671251040482f837ed312deb10efe

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial

Authors: Kate Cwynarski, Gloria Iacoboni, Eleni Tholouli, Tobias Menne, David A. Irvine, Nivetha Balasubramaniam, Leigh Wood, Justin Shang, Eric Xue, Yiyun Zhang, Silvia Basilico, Margarida Neves, Meera Raymond, Ian Scott, Mohamed El-Kholy, Ram Jha, Heather Dainton-Smith, Rehan Hussain, William Day, Mathieu Ferrari, Simon Thomas, Koki Lilova, Wolfram Brugger, Teresa Marafioti, Pierre Lao-Sirieix, Paul Maciocia, Martin Pule

Contributors: Institut Català de la Salut, [Cwynarski K] Department of Haematology, University College London, London, UK. University College London Hospital, London, UK. [Iacoboni G] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Tholouli E] Department of Haematology, Manchester Royal Infirmary, Manchester, UK. [Menne T] The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. [Irvine DA] Queen Elizabeth University Hospital, Glasgow, UK. [Balasubramaniam N] University College London Hospital, London, UK, Vall d'Hebron Barcelona Hospital Campus

Source: Nat Med
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: 0301 basic medicine, Sistema limfàtic - Càncer - Immunoteràpia, ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T, Other subheadings::Other subheadings::/therapy, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células T::linfoma de células T periféricas, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, T-Cell::Lymphoma, T-Cell, Peripheral, Article, Limfomes - Immunoteràpia, 03 medical and health sciences, Otros calificadores::Otros calificadores::/terapia, 0302 clinical medicine, Cèl·lules T, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39528665
https://hdl.handle.net/11351/12688

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

Authors: Anne Mea Spanjaart, Per Ljungman, Gloria Tridello, Juana Schwartz, Nuria Martinez-Cibrián, Pere Barba, Mi Kwon, Lucia Lopez-Corral, Joaquin Martinez-Lopez, Christelle Ferra, Roberta Di Blasi, Hervé Ghesquieres, Pim Mutsaers, Friso Calkoen, Margot Jak, Jaap van Doesum, Joost S. P. Vermaat, Marjolein van der Poel, Johan Maertens, Massimiliano Gambella, Elisabetta Metafuni, Fabio Ciceri, Riccardo Saccardi, Emma Nicholson, Eleni Tholouli, Collin Matthew, Victoria Potter, Adrian Bloor, Caroline Besley, Claire Roddie, Keith Wilson, Arnon Nagler, Antonio Campos, Soeren Lykke Petersen, Frantisek Folber, Peter Bader, Jurgen Finke, Nicolaus Kroger, Nina Knelange, Rafael de La Camara, Marie José Kersten, Stephan Mielke

Contributors: Institut Català de la Salut, [Spanjaart AM] Department of Hematology, Amsterdam UMC location University of Amsterdam, Cancer Center Amsterdam and LYMMCARE, Amsterdam, The Netherlands. [Ljungman P] Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden. [Tridello G] European Society for Blood and Marrow Transplantation (EBMT) Data Office, Department of Medical Statistics & Bioinformatics, Leiden, Netherlands. [Schwartz J] European Society for Blood and Marrow Transplantation (EBMT) Leiden Study Unit, European Society for Blood and Marrow Transplantation (EBMT) Data Office, Leiden, Netherlands. [Martinez-Cibrián N] Department of Hematology, Hospital Clínic, Barcelona, Spain. [Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, MS Hematologie, Cancer, Infection & Immunity, Maire, Magali, Cancer Center Amsterdam and LYMMCARE, Amsterdam, Karolinska University Hospital Stockholm, Leiden University Medical Center (LUMC), Universiteit Leiden = Leiden University, Azienda Ospedaliera Universitaria Integrata of Verona, European Society for Blood and Marrow Transplantation (EBMT), Vall d'Hebron University Hospital Barcelona, Instituto de Investigación Sanitaria Gregorio Marañón / Institute of Health Research Gregorio Marañón Madrid, Spain (IiSGM), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca España = University of Salamanca Spain, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Hopital Saint-Louis AP-HP (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Cité (UPCité), Immuno-Biologie des Lymphomes CIRI (CIRI-LIB), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d’Hématologie Centre Hospitalier Lyon Sud - HCL, Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Erasmus University Medical Center Rotterdam (Erasmus MC), University Medical Center Groningen Groningen (UMCG), Universitair Ziekenhuis Leuven (UZ Leuven)

Source: Leukemia
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)

Subject Terms: Male, Cancer Research, [SDV]Life Sciences [q-bio], COVID-19 (Malaltia) - Mortalitat, Immunotherapy, Adoptive, DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Child, Receptors, Chimeric Antigen, COVID-19, COVID-19/immunology [MeSH], Aged [MeSH], Receptors, Chimeric Antigen/immunology [MeSH], COVID-19/therapy [MeSH], COVID-19/mortality [MeSH], Male [MeSH], SARS-CoV-2/immunology [MeSH], Child [MeSH], Hematologic Neoplasms/mortality [MeSH], Adolescent [MeSH], Female [MeSH], Immunotherapy, Adoptive/adverse effects [MeSH], Adult [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Europe/epidemiology [MeSH], Survival Rate [MeSH], Article, Hematologic Neoplasms/therapy [MeSH], Young Adult [MeSH], 631/250/251, 631/67/1990, Hematologic Neoplasms/immunology [MeSH], Immunotherapy, Adoptive/methods [MeSH], article, Child, Preschool [MeSH], Sang - Malalties - Immunoteràpia, Hematology, Middle Aged, 3. Good health, [SDV] Life Sciences [q-bio], Europe, Survival Rate, Otros calificadores::Otros calificadores::/terapia, Treatment Outcome, Oncology, Hematologic Neoplasms, Child, Preschool, VACCINATION, Female, 3201 Cardiovascular medicine and haematology, Life Sciences & Biomedicine, Adult, Adolescent, Immunology, Other subheadings::Other subheadings::/therapy, SARS-COV-2, Young Adult, SDG 3 - Good Health and Well-being, 3211 Oncology and carcinogenesis, DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms, Humans, 1112 Oncology and Carcinogenesis, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus, Aged, Other subheadings::Other subheadings::Other subheadings::Other subheadings::/mortality, Science & Technology, SARS-CoV-2, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, 3202 Clinical sciences, 1103 Clinical Sciences, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Otros calificadores::Otros calificadores::Otros calificadores::Otros calificadores::/mortalidad, Avaluació de resultats (Assistència sanitària), ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas

File Description: application/pdf; pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39043963
https://hdl.handle.net/11351/12651
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15097
https://dspace.library.uu.nl/handle/1874/455493
https://pure.amsterdamumc.nl/en/publications/b1e47daf-4a42-4db4-a824-b8b34f6c134e
https://doi.org/10.1038/s41375-024-02336-1
https://lirias.kuleuven.be/handle/20.500.12942/752756
https://doi.org/10.1038/s41375-024-02336-1
https://hal.science/hal-04921717v1
https://doi.org/10.1038/s41375-024-02336-1
https://repository.publisso.de/resource/frl:6519899

Unlocking the potential of engineered immune cell therapy for solid tumors

Authors: Víctor Albarrán-Fernández, Laura Angelats, Julio Delgado, Alena Gros, Álvaro Urbano-Ispizua, Sònia Guedan, Aleix Prat

Contributors: Institut Català de la Salut, [Albarrán-Fernández V, Angelats L] Medical Oncology Department, Hospital Clínic, Barcelona, Spain. Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [Delgado J, Urbano-Ispizua Á] Oncoimmunotherapy Unit, Department of Hematology, Hospital Clínic, Barcelona, Spain. Department of Medicine, University of Barcelona, Barcelona, Spain. [Gros A] Tumor Immunology and Immunotherapy, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Gueda S] Cellular Immunotherapies for Cancer, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Nat Commun
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Nature Communications, Vol 16, Iss 1, Pp 1-5 (2025)

Subject Terms: TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, DISEASES::Neoplasms, Otros calificadores::Otros calificadores::/terapia, ENFERMEDADES::neoplasias, Science, Teràpia cel·lular, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Comment, Other subheadings::Other subheadings::/therapy, Càncer - Immunoteràpia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva

File Description: application/pdf

Access URL: http://hdl.handle.net/11351/12860
https://doaj.org/article/87e7c28d952649038ad306c7696c5748

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Authors: Rejeski, Kai, Wang, Yucai, Hansen, Doris, Iacoboni, Gloria, Bachy, Emmanuel, Bansal, Radhika, Penack, Olaf, Müller, Fabian, Bethge, Wolfgang, Munoz, Javier, Mohty, Razan, Bücklein, Veit, Barba, Pere, Locke, Frederick, Lin, Yi, Jain, Michael, Subklewe, Marion

Contributors: Institut Català de la Salut, [Rejeski K] Department of Medicine III – Hematology/Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich and Berlin Sites, and German Cancer Research Center, Heidelberg, Germany. Adult BMT and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY. [Wang Y, Bansal R] Division of Hematology, Mayo Clinic, Rochester, MN. [Hansen DK] Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL. [Iacoboni G, Barba P] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Bachy E] Department of Hematology, Lyon Sud Hospital, INSERM 1052, Pierre-Bénite, France, Vall d'Hebron Barcelona Hospital Campus, Maire, Magali, Ludwig Maximilian University Munich = Ludwig Maximilians Universität München (LMU), University of Science and Technology of China Hefei (USTC), H. Lee Moffitt Cancer Center and Research Institute, Vall d'Hebron University Hospital Barcelona, Immuno-Biologie des Lymphomes CIRI (CIRI-LIB), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d’Hématologie Centre Hospitalier Lyon Sud - HCL, Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Mayo Clinic Rochester, Charité - UniversitätsMedizin = Berlin University Medicine, Laboratoire de Psychologie Sociale : contextes et régulation (LPS (URP_4471)), Université Paris Cité (UPCité), Eberhard Karls Universität Tübingen = University of Tübingen, The University of Texas M.D. Anderson Cancer Center Houston, American University of Beirut Faculty of Medicine and Medical Center (AUB), University Hospital LMU Munich, LMU Gene Center, Munich, Department of Computer Science and Information System, Peking University

Source: Blood Adv
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Adult, 0301 basic medicine, Neutropenia, Immunobiology and Immunotherapy, [SDV]Life Sciences [q-bio], ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B, Lymphoma, Mantle-Cell, Cèl·lules T - Ús terapèutic, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell, 03 medical and health sciences, 0302 clinical medicine, Humans, Adaptor Proteins, Signal Transducing, Neutropènia, Receptors, Chimeric Antigen, Incidence, Mieloma múltiple, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos leucocitarios::leucopenia::agranulocitosis::neutropenia, [SDV] Life Sciences [q-bio], ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia, Cytopenia, Cèl·lules B - Tumors, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas, Multiple Myeloma

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38181508
https://hdl.handle.net/11351/11330

Mapping MAGE-A4 expression in solid cancers for targeted therapies

Authors: Christin Habigt, Sylvie Rottey, Iben Spanggaard, Juanita S. Lopez, Elena Garralda, Emiliano Calvo, Oliver Bechter, Jayesh Desai, Rachel Galot, Leena Gandhi, Florian Heil, Natascha Rieder, Ivan Dimitrov, Iris Martinez Quetglas, Christian Heichinger, Nino Keshelava, Andreas Roller

Contributors: Institut Català de la Salut, [Habigt C] Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich, Penzberg, Germany. [Rottey S] Department of Medical Oncology, UZ Gent, Ghent, Belgium. [Spanggaard I] Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. [Lopez JS] Phase I Drug Development Unit, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom. [Garralda E] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Calvo E] START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Front Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Frontiers in Oncology, Vol 15 (2025)

Subject Terms: TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Science & Technology, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Càncer - Tractament, 3202 Clinical sciences, CHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Neoplasm, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Antígens tumorals, clinical trial, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos tumorales, DISEASES::Neoplasms, Oncology, ENFERMEDADES::neoplasias, 3211 Oncology and carcinogenesis, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, biomarker, Càncer - Immunoteràpia, 1112 Oncology and Carcinogenesis, translational analysis, Life Sciences & Biomedicine, target expression, RC254-282, patient selection

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/40151801
http://hdl.handle.net/11351/13328
https://doaj.org/article/b27fe0d2c45a4c8997c746a18fcf9b6f
https://lirias.kuleuven.be/handle/20.500.12942/763286
https://doi.org/10.3389/fonc.2025.1484182

Chimeric antigen receptor T‐cell therapy outcomes in T cell/histiocyte‐rich large B‐cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

Authors: Mariana Bastos‐Oreiro, Gloria Iacoboni, Víctor N. Garcés, Ana C. Caballero, Nuria Martínez, Javier Delgado, Aitana Balaguer, Mi Kwon, Sonia Gonzalez de Villambrosia, Rafael Hernani, Ana Jimenez‐Ubieto, Rebeca Bailen, Izaskun Zaberio, Alejandro Martín García‐Sancho, Pere Barba

Contributors: Institut Català de la Salut, [Bastos‐Oreiro M] Hematology Department, Hospital General Universitario Gregorio Marañon, Instituto de investigación sanitaria Gregorio Marañon, Madrid, Spain. [Iacoboni G] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Garcés VN, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Caballero AC] Department d’hematologia, Hospital Sant Pau, Barcelona, Spain. [Martínez N] Servei d'Hematologia, Hospital Clínic, Barcelona, Spain. [Delgado J] Hematology Department, Virgen del Rocío, Sevilla, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Hemasphere
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
HemaSphere, Vol 9, Iss 2, Pp n/a-n/a (2025)

Subject Terms: DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Cèl·lules B - Tumors - Immunoteràpia, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Letter, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::progresión de la enfermedad, Avaluació de resultats (Assistència sanitària), Diseases of the blood and blood-forming organs, RC633-647.5, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression

File Description: application/pdf

Access URL: http://hdl.handle.net/11351/12787
https://doaj.org/article/5a4be9e91e204d37bf8e463f492f5ad6

Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma

Authors: Winkelmann, Michael, Raj, Sandeep S., Müller, Fabian, Hansmann, Leo, Jain, Michael, IACOBONI, GLORIA, Barba, Pere

Contributors: Institut Català de la Salut, Winkelmann M Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany. German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and LMU University Hospital, Munich, Germany. Raj SS Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Jain MD Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, USA. Iacoboni G, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Müller F Bavarian Cancer Research Center (BZKF), partner sites Munich and Erlangen, Munich, Germany. Department of Internal Medicine 5 - Hematology and Oncology, University Hospital of Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Hansmann L Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia

Subject Terms: Limfomes - Immunoteràpia, Cèl·lules B - Tumors - Immunoteràpia, Receptors cel·lulars, Limfomes - Prognosi, Cèl·lules B - Tumors - Prognosi, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::/therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Artificial::Receptors, Chimeric Antigen, AND EQUIPMENT::Diagnosis::Prognosis, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::/terapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores artificiales::receptores de antígenos quiméricos, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico

File Description: application/pdf

Relation: Blood Cancer Journal;15; https://doi.org/10.1038/s41408-025-01338-1; https://hdl.handle.net/11351/13961; 001559434000001

Availability: https://hdl.handle.net/11351/13961
https://doi.org/10.1038/s41408-025-01338-1

Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy

Authors: Feijoo, Samantha, Vilaseca Jolonch, Andreu, Ariño, Helena, IACOBONI, GLORIA, Zabalza, Ana, Fissolo, Nicolás Miguel, AREVALO, MARIA JESUS, Cecilia del Carmen, Carpio Segura, Sanchez-Salinas, Mario Andrés, Tintore, Mar, Comabella Lopez, Manuel, Barba, Pere, Vidal-Jordana, Angela, Montalban, Xavier

Contributors: Institut Català de la Salut, Vilaseca A, Ariño H, Zabalza A, Fissolo N, Arévalo MJ, Comabella M, Vidal-Jordana Á Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Iacoboni G, Feijóo S, Carpio C, Sánchez M Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Tintoré M, Montalban X Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Universitat de Vic-Universitat Central de Catatlunya (UVic-UCC), Vic, Spain. Barba P Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia

Subject Terms: Marcadors bioquímics, Filaments citoplasmàtics, Neurotoxicologia, Sistema nerviós - Malalties - Diagnòstic, Immunoteràpia, Teràpia cel·lular, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Other subheadings::Other subheadings::Other subheadings::/adverse effects, CHEMICALS AND DRUGS::Biological Factors::Biomarkers, CHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament Proteins, DISEASES::Nervous System Diseases::Neurotoxicity Syndromes, Other subheadings::Other subheadings::/diagnosis, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores, COMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentos, ENFERMEDADES::enfermedades del sistema nervioso::síndromes de neurotoxicidad, Otros calificadores::Otros calificadores::/diagnóstico

File Description: application/pdf

Relation: European Journal of Neurology;32(8); https://doi.org/10.1111/ene.70305; https://hdl.handle.net/11351/13761; 001562661300008

Availability: https://hdl.handle.net/11351/13761
https://doi.org/10.1111/ene.70305

Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Authors: Bailén, Rebeca, Benzaquén Vallejos, Ana, Camacho-Arteaga, Lina, IACOBONI, GLORIA, Kwon, Mi, Hernani, Rafael, Alonso-Martínez, Carla, Vidal, Xavier, Barba, Pere, Agustí, Antònia

Contributors: Institut Català de la Salut, Camacho-Arteaga L, Agustí A Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca de Farmacologia Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Iacoboni G, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. Kwon M Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Institute of Health Resarch Gregorio Marañón, Madrid, Spain. Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain. Bailén R Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Institute of Health Resarch Gregorio Marañón, Madrid, Spain. Hernani R, Benzaquén A Hematology Department, Hospital Clínico Universitario, INCLIVA Research Institute Valencia, Spain. Alonso-Martínez C Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vidal X Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia

Subject Terms: Cèl·lules B - Tumors - Immunoteràpia, Cèl·lules T - Receptors, Medicaments - Efectes secundaris, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Other subheadings::Other subheadings::Other subheadings::/adverse effects, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::/therapy, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Artificial::Receptors, Chimeric Antigen, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::/terapia, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores artificiales::receptores de antígenos quiméricos

File Description: application/pdf

Relation: JAMA Network Open;8(2); https://doi.org/10.1001/jamanetworkopen.2024.61683; http://hdl.handle.net/11351/12882; 001434690700002

Availability: http://hdl.handle.net/11351/12882
https://doi.org/10.1001/jamanetworkopen.2024.61683

Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?

Authors: Mario Andrés Sánchez-Salinas, Marta Miarons, Iñaki F. Troconiz, Víctor Navarro, Javier Varela, Gloria Iacoboni, Pere Barba

Contributors: Institut Català de la Salut, [Sanchez-Salinas MA, Iacoboni G, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Miarons M] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Pharmacy Department, Consorci Hospitalari de Vic, Barcelona, Spain. [Troconiz IF] Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain. [Navarro V] Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Varela J] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Blood Adv
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Male, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Receptors, Chimeric Antigen, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores artificiales::receptores de antígenos quiméricos, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Limfomes - Quimioteràpia, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Artificial::Receptors, Chimeric Antigen, Antineoplastic Agents, Cèl·lules T - Ús terapèutic, Immunotherapy, Adoptive, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Commentary, Humans, Cèl·lules B - Tumors, Vidarabine, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38231085
https://hdl.handle.net/11351/11467

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma

Authors: Di Staso, Rossana, Casadei, Beatrice, Locke, Frederick, D. Jain, Michael, Voorhees, Timothy, S Kittai, Adam, Bastos-Oreiro, Mariana, Gutiérrez, Antonio, Martin Garcia-Sancho, Alejandro, Terol, Maria Jose, Mead, Monica, J. Maranzano, Michael, Iacoboni, Gloria, Barba, Pere, Kwon, Mi, Bailén-Almorox, Rebeca, Reguera Ortega, Juan Luis, Mian, Agrima, Hill, Brian, Bachy, Emmanuel, Morschhauser, Franck, Houot, Roch, Thieblemont, Catherine, Le Gouill, Steven, Masetti, Riccardo, Gori, Davide, Broccoli, Alessandro, Zinzani, Pier Luigi, Argnani, Lisa

Contributors: Institut Català de la Salut, [Di Staso R] Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. [Casadei B] IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy. [Locke FL, Jain M] Moffitt Cancer Center, Tampa, FL, USA. [Voorhees TJ, Kittai AS] Division of Hematology, The Ohio State University, Columbus, OH, USA. [Iacoboni G, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Jonchère, Laurent

Source: Blood Cancer J
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)

Subject Terms: 0301 basic medicine, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Cèl·lules B - Tumors - Immunoteràpia, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Clinical trial design, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Cèl·lules T, CAR T, therapeutic pathway, real world studies, cell therapy, relapsed refractory diffuse large B cell lymphoma, Correspondence, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, RC254-282, Haematological diseases

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39511146
https://hdl.handle.net/11351/12439
https://doaj.org/article/43e03c8577e3401699a0eac8f43eb23f
https://ddd.uab.cat/record/306718
https://hal.science/hal-04780223v1
https://hal.science/hal-04780223v1/document
https://doi.org/10.1038/s41408-024-01183-8
https://www.nature.com/articles/s41408-024-01183-8
https://doi.org/10.1038/s41408-024-01183-8
https://hdl.handle.net/11585/997492

The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

Authors: Rejeski, Kai, Wang, Yucai, Albanyan, Omar, Munoz, Javier, Sesques, Pierre, Iacoboni, Gloria, Lopez-Corral, Lucia, Ries, Isabelle, Bücklein, Veit, Mohty, Razan, Dreyling, Martin, Baluch, Aliyah, Shah, Bijal, Locke, Frederick, Hess, Georg, Barba, Pere, Bachy, Emmanuel, Lin, Yi, Subklewe, Marion, Jain, Michael

Contributors: Institut Català de la Salut, [Rejeski K] Department of Medicine III – Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany. [Wang Y] Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. [Albanyan O] Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. [Munoz J] Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA. [Sesques P] Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, Pierre-Bénite, France. [Iacoboni G] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Medicine, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Maire, Magali, Ludwig Maximilian University Munich = Ludwig Maximilians Universität München (LMU), University of Science and Technology of China Hefei (USTC), Moffitt Cancer Center Tampa, FL, USA (M2C), The University of Texas M.D. Anderson Cancer Center Houston, Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL), Vall d'Hebron University Hospital Barcelona, Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca España = University of Salamanca Spain, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), University Medical Center of the Johannes Gutenberg-University Mainz, University Hospital LMU Munich, LMU Gene Center, Munich, American University of Beirut Faculty of Medicine and Medical Center (AUB), Infectious Diseases, Moffitt Cancer Center, Tampa, H. Lee Moffitt Cancer Center and Research Institute, Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), Immuno-Biologie des Lymphomes CIRI (CIRI-LIB), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d’Hématologie Centre Hospitalier Lyon Sud - HCL, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Tongji University

Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, Neutropenia, [SDV]Life Sciences [q-bio], ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Mantle-Cell, Lymphoma, Mantle-Cell, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células del manto, Trastorns limfoproliferatius - Tractament, Immunotherapy, Adoptive, Progression-Free Survival, 3. Good health, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, [SDV] Life Sciences [q-bio], Treatment Outcome, Other subheadings::Other subheadings::Other subheadings::/adverse effects, Limfomes - Tractament, Humans, Cèl·lules T - Ús terapèutic - Efectes secundaris, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37584447
https://hdl.handle.net/11351/10464
https://hal.science/hal-04923575v1
https://doi.org/10.1002/ajh.27056
https://epub.ub.uni-muenchen.de/108997/

Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma

Authors: Sesques, P., Kirkwood, A. A., Kwon, M., Rejeski, K., Jain, M. D., Di Blasi, R., Brisou, G., Gros, F. X., Le Bras, F., Bories, P., Choquet, S., Rubio, M. T., Iacoboni, G., O'Reilly, M., Casasnovas, R. O., Bay, J. O., Mohty, M., Joris, M., Abraham, J., Castilla Llorente, C., Loschi, M., Carras, S., Chauchet, A., La Rochelle, L. D., Hermine, O., Guidez, S., Cony-Makhoul, P., Fogarty, P., Le Gouill, S., Morschhauser, Franck, Gastinne, T., Cartron, G., Subklewe, M., Locke, F. L., Sanderson, R., Barba, P., Houot, R., Bachy, E.

Contributors: Institut Català de la Salut, [Sesques P] Hematology Department, Hospices Civils de Lyon, Lyon, France. [Kirkwood AA] Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK. [Kwon M] Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Rejeski K] Department of Medicine III – Hematology/Oncol ogy, LMU University Hospital, LMU Munich, Munich, Germany. [Jain MD] Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moftt Cancer Center, Tampa, USA. [Di Blasi R] Hematology Department, Hôpital Saint Louis, Paris, France. [Iacoboni G, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Université de Lille, LillOA, Hospices Civils de Lyon (HCL), University College of London London (UCL), Hospital General Universitario 'Gregorio Marañón' Madrid, Ludwig Maximilian University Munich = Ludwig Maximilians Universität München (LMU), H. Lee Moffitt Cancer Center and Research Institute, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), King‘s College London, Vall d'Hebron Institute of Oncology Barcelone (VHIO), Vall d'Hebron University Hospital Barcelona, Centre Hospitalier Universitaire Rennes, Service d’Hématologie Centre Hospitalier Lyon Sud - HCL, Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Immuno-Biologie des Lymphomes CIRI (CIRI-LIB), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Source: J Hematol Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-10 (2024)

Subject Terms: Male, Adult, Cèl·lules B - Tumors - Immunoteràpia, Prognosi, [SDV]Life Sciences [q-bio], Antigens, CD19, Immunoteràpia, Other subheadings::Other subheadings::/therapy, Receptors, Antigen, T-Cell, Biological Products/therapeutic use [MeSH], Female [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Immunotherapy, Adoptive/adverse effects [MeSH], Neurotoxicity Syndromes/etiology [MeSH], Adult [MeSH], Humans [MeSH], Middle Aged [MeSH], France [MeSH], Antigens, CD19/immunology [MeSH], Lymphoma, Large B-Cell, Diffuse/immunology [MeSH], Lymphoma, Large B-Cell, Diffuse/therapy [MeSH], Male [MeSH], Cytokine Release Syndrome/etiology [MeSH], Research, Biological Products/adverse effects [MeSH], Prognosis [MeSH], Receptors, Antigen, T-Cell [MeSH], Immunotherapy, Adoptive/methods [MeSH], Immunotherapy, Adoptive, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, Humans, Diseases of the blood and blood-forming organs, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, RC254-282, SIndrome Tormenta Citocinas, Aged, Aged, 80 and over, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Biological Products, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Middle Aged, Prognosis, 3. Good health, [SDV] Life Sciences [q-bio], Otros calificadores::Otros calificadores::/terapia, Other subheadings::Other subheadings::Other subheadings::/adverse effects, Citocines, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis, Female, Neurotoxicity Syndromes, Lymphoma, Large B-Cell, Diffuse, France, RC633-647.5, Cytokine Release Syndrome, Antígens - Receptors

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39107847
https://hdl.handle.net/11351/12029
https://doaj.org/article/8b4e23a2ec6b43d29b08dcb92f281971
https://repository.publisso.de/resource/frl:6508604

A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Authors: M Lia Palomba, Paola Ghione, Anik R Patel, Myrna Nahas, Sara Beygi, Anthony J Hatswell, Steve Kanters, Eve H. Limbrick-Oldfield, Sally W Wade, Markqayne D Ray, Jessica Owen, Sattva S Neelapu, John Gribben, John Radford, Sabela Bobillo

Contributors: Institut Català de la Salut, [Palomba ML, Ghione P] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Patel AR, Nahas M, Beygi S] Kite, A Gilead Company, Santa Monica, CA, USA. [Hatswell AJ] Delta Hat, Nottingham, UK. [Bobillo S] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Expert Rev Anticancer Ther
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Palomba, M L, Ghione, P, Patel, A R, Nahas, M, Beygi, S, Hatswell, A J, Kanters, S, Limbrick-Oldfield, E H, Wade, S W, Ray, M D, Owen, J, Neelapu, S S, Gribben, J, Radford, J & Bobillo, S 2023, 'A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma', Expert Review of Anticancer Therapy, vol. 23, no. 2, pp. 199-206. https://doi.org/10.1080/14737140.2023.2171994

Subject Terms: Cèl·lules B - Tumors - Immunoteràpia, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, comparative effectiveness, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Follicular, propensity score analysis, Immunotherapy, Adoptive, Article, Follicular lymphoma, Limfomes - Immunoteràpia, 03 medical and health sciences, 0302 clinical medicine, follicular lymphoma, Humans, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Lymphoma, Follicular, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma folicular, Biological Products, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Manchester Cancer Research Centre, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, Progression-Free Survival, axicabtagene ciloleucel, 3. Good health, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Avaluació de resultats (Assistència sanitària), Lymphoma, Large B-Cell, Diffuse, ZUMA-5

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/36723678
https://hdl.handle.net/11351/9115
https://discovery-pp.ucl.ac.uk/id/eprint/10164359/

Efficacy and safety of bendamustine‐containing bridging therapy in R/R LBCL patients receiving CD19 CAR T‐cells

Authors: Gloria Iacoboni, Mario A. Sánchez‐Salinas, Kai Rejeski, Ana Á. Martín‐López, Mi Kwon, Víctor Navarro, Katarzyna A. Jalowiec, Rafael Hernani, Juan L. Reguera‐Ortega, Laura Gallur, Viktoria Blumenberg, María Herrero‐García, Claire Roddie, Ana Benzaquén, Javier Delgado‐Serrano, Rebeca Bailén, Cecilia Carpio, Paula Amat, Lucia López‐Corral, Lourdes Martín‐Martín, Mariana Bastos, Marion Subklewe, Maeve O'Reilly, Pere Barba

Contributors: Instituto de Salud Carlos III, Asociación Española Contra el Cáncer, Generalitat de Catalunya, Iacoboni, Gloria [0000-0003-0805-9288], Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72], Institut Català de la Salut, [Iacoboni G, Sánchez‐Salinas MA, Gallur L, Carpio C, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Rejeski k] Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany. Adult BMT and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. [Martín‐López AÁ] Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain. Centro de Investigación del Cáncer‐IBMCC, Salamanca, Spain. [Kwon M] Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain. [Navarro V] Oncology Data Science (ODySey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Hemasphere
Digital.CSIC. Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
HemaSphere, Vol 8, Iss 7, Pp n/a-n/a (2024)

Subject Terms: 0301 basic medicine, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, 0303 health sciences, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Cèl·lules B - Tumors - Tractament, Medicaments antineoplàstics - Ús terapèutic, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Articles, Cèl·lules T - Ús terapèutic, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, 3. Good health, 03 medical and health sciences, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos, Avaluació de resultats (Assistència sanitària), Diseases of the blood and blood-forming organs, RC633-647.5, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38948924
http://hdl.handle.net/10261/371028
https://api.elsevier.com/content/abstract/scopus_id/85197400097
https://hdl.handle.net/11351/11672
https://doaj.org/article/cdbf64d4db8243168467791d3772b7b2

Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy

Authors: Gloria Iacoboni, Josu Iraola‐Truchuelo, Maeve O'Reilly, Víctor Navarro, Tobias Menne, Mi Kwon, Ana África Martín‐López, Sridhar Chaganti, Javier Delgado, Claire Roddie, Ariadna Pérez, Jane Norman, Manuel Guerreiro, Adam Gibb, Ana Carolina Caballero, Caroline Besley, Nuria Martínez‐Cibrián, Alberto Mussetti, Robin Sanderson, Hugo Luzardo, Sunil Iyengar, Jose Maria Sánchez, Ceri Jones, Juan‐Manuel Sancho, Pere Barba, Anne‐Louise Latif, Lucia López‐Corral, Rafael Hernani, Juan Luis Reguera, Anna Sureda, Alejandro Martin Garcia‐Sancho, Mariana Bastos, Pau Abrisqueta, Andrea Kuhnl

Contributors: Iacoboni, Gloria [0000-0003-0805-9288], Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72], Institut Català de la Salut, [Iacoboni G, Barba P, Abrisqueta P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Iraola‐Truchuelo J] Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [O’Reilly M] Department of Hematology, University College London Hospitals, London, UK. [Navarro V] Oncology Data Science (ODySey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Menne T] Department of Hematology, Freeman Hospital, Newcastle, UK. [Kwon M] Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Hemasphere
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Dipòsit Digital de la UB
instname
Digital.CSIC. Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
HemaSphere, Vol 8, Iss 5, Pp n/a-n/a (2024)

Subject Terms: 0301 basic medicine, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Limfomes, 0303 health sciences, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Immunoteràpia, Cèl·lules B - Tumors - Tractament, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Articles, Cèl·lules T - Ús terapèutic, Immunotheraphy, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, 3. Good health, 03 medical and health sciences, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Avaluació de resultats (Assistència sanitària), Limfomes - Tractament, Diseases of the blood and blood-forming organs, Lymphomas, RC633-647.5, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38774657
https://hdl.handle.net/2445/214571
https://api.elsevier.com/content/abstract/scopus_id/85193738170
http://hdl.handle.net/10261/370664
https://hdl.handle.net/11351/11604
https://doaj.org/article/da69c64401f4489eb88ab02b2a46bb49
https://ddd.uab.cat/record/301968
http://hdl.handle.net/2445/214571

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

Authors: Rejeski, Kai, Burchert, Andreas, Iacoboni, Gloria, Sesques, Pierre, Fransecky, Lars, Bücklein, Veit, Trenker, Corinna, Hernani, Rafael, Naumann, Ralph, Schäfer, Jonas, Blumenberg, Viktoria, Schmidt, Christian, Sohlbach, Kristina, von Bergwelt-Baildon, Michael, Bachy, Emmanuel, Barba, Pere, Subklewe, Marion

Contributors: Institut Català de la Salut, [Rejeski K] Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany. [Burchert A] Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany. [Iacoboni G, Barba P] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma of Barcelona, Bellaterra, Spain. [Sesques P] Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, Pierre-B enite, France. [Fransecky L] Medical Department II–Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany. [Bücklein V] Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany, Vall d'Hebron Barcelona Hospital Campus, Maire, Magali, Ludwig Maximilian University Munich = Ludwig Maximilians Universität München (LMU), Philipps University Marburg and University Hospital Giessen and Marburg, Vall d'Hebron University Hospital Barcelona, Service d’Hématologie Centre Hospitalier Lyon Sud - HCL, Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Christian-Albrechts University and University Hospital Schleswig-Holstein, Campus Kiel, University Hospital LMU Munich, LMU Gene Center, Munich, Hospital Clínico Universitario, Institute for Research INCLIVA, Valencia, Solvay Brussels School of Economics and Management Brussels (ULB), Université libre de Bruxelles (ULB), German Cancer Research Center - Deutsches Krebsforschungszentrum Heidelberg (DKFZ), Immuno-Biologie des Lymphomes CIRI (CIRI-LIB), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Philosophie, Histoire et Analyse des Représentations Économiques (PHARE), Université Paris 1 Panthéon-Sorbonne (UP1)

Source: Blood Adv
Blood Advances
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut

Subject Terms: TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Salvage Therapy, [SDV]Life Sciences [q-bio], Teràpia cel·lular, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento de última línea, Stem Cells, Antigens, CD19, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Salvage Therapy, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios de viabilidad, Immunotherapy, Adoptive, 3. Good health, [SDV] Life Sciences [q-bio], ANATOMÍA::células::células madre, 03 medical and health sciences, Estudis de viabilitat, ANATOMY::Cells::Stem Cells, 0302 clinical medicine, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Research Letter, Feasibility Studies, Cèl·lules mare, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Feasibility Studies

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/35793454
https://incliva.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16880
https://hdl.handle.net/11351/9612
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16880
https://ddd.uab.cat/record/268210

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Authors: Gloria Iacoboni, Kai Rejeski, Guillermo Villacampa, Jaap A. van Doesum, Annalisa Chiappella, Francesca Bonifazi, Lucia Lopez-Corral, Michiel van Aalderen, Mi Kwon, Nuria Martínez-Cibrian, Stefania Bramanti, Juan Luis Reguera-Ortega, Lina Camacho-Arteaga, Christian Schmidt, Ana Marín-Niebla, Marie José Kersten, Alejandro Martin Garcia-Sancho, Pier Luigi Zinzani, Paolo Corradini, Tom van Meerten, Marion Subklewe, Pere Barba

Contributors: Institut Català de la Salut, [Iacoboni G, Marín-Niebla A, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Rejeski K] Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. [Villacampa G] Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. The Institute of Cancer Research, London, United Kingdom. [van Doesum JA] Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. [Chiappella A] Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy. [Bonifazi F] IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 'Seragnoli', Bologna, Italy. [Camacho-Arteaga L] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Farmacologia Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Blood Adv
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Iacoboni, G, Rejeski, K, Villacampa, G, van Doesum, J A, Chiappella, A, Bonifazi, F, Lopez-Corral, L, van Aalderen, M, Kwon, M, Martınez-Cibrian, N, Bramanti, S, Reguera-Ortega, J L, Camacho-Arteaga, L, Schmidt, C, Marın-Niebla, A, Kersten, M J, Garcia-Sancho, A M, Zinzani, P L, Corradini, P, van Meerten, T, Subklewe, M & Barba, P 2022, 'Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma', Blood, vol. 6, no. 12, pp. 3606-3610. https://doi.org/10.1182/bloodadvances.2021006922

Subject Terms: TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Adult, 0301 basic medicine, 0303 health sciences, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Receptors, Chimeric Antigen, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Teràpia cel·lular, Antineoplastic Agents, Lymphoma, Mantle-Cell, Immunotherapy, Adoptive, 03 medical and health sciences, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células del manto, Pyrimidines, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Research Letter, Limfomes - Tractament, Humans, Neoplasm Recurrence, Local, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Mantle-Cell, Real-world, brexucabtagene autoleucel, relapsed refractory, mantle cell lymphoma

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/35271707
https://hdl.handle.net/11351/9613
http://hdl.handle.net/10668/20251
https://research.vumc.nl/en/publications/3971a403-0b9e-45ce-af9b-d21fb5c89489
https://ddd.uab.cat/record/268212
https://hdl.handle.net/10668/20251